Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Filing type: Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS).
Proposed sale: 10,000 shares of Common Stock through Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) on 08/06/2025, with an aggregate market value of $419,292.00. The filing lists 159,391,229 shares outstanding.
Acquisition details: 42,223 shares were acquired as Restricted Stock Units on 01/15/2017; payment: Cash. The filing shows "Nothing to Report" for securities sold in the past 3 months. The filer identity/CIK and submission contact fields are not provided in the form content.
Ionis Pharmaceuticals (IONS) filed a Form 4 stating that EVP & Chief Clinical Development Officer Eugene Schneider sold 9,549 common shares on 08/04/2025 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted 05/02/2025. The weighted-average sale price was $42.8004, with individual trades executed between $42.315 and $43.45. Gross proceeds are roughly $0.41 million.
Following the disposition, Schneider directly owns 51,507 shares; the sale reduced his direct stake by approximately 15.6 % (from 61,056 shares). No derivative securities were involved. The filing is a routine Section 16 disclosure and does not affect the company’s operations or guidance.
Q2-25 results (ended 30 Jun 25): Ionis generated $452.0 M revenue, +101% YoY, fuelled by a $280 M upfront from Ono (sapablursen), a $30 M milestone from AstraZeneca and $19.3 M of first-time U.S. TRYNGOLZA sales. Royalty streams (mostly SPINRAZA & WAINUA) added $70.0 M.
Operating expenses rose 7% to $312.2 M as SG&A expanded with launches while R&D fell modestly; operating profit reached $139.8 M versus a $66.1 M loss. Net income swung to $123.6 M ($0.70 diluted EPS) from a $66.3 M loss.
H1-25: Revenue climbed 69% to $583.7 M; net loss narrowed to $23.4 M. Operating cash flow was essentially breakeven ( $0.6 M) versus a $269.8 M outflow a year earlier.
Balance sheet: Cash increased to $297.3 M; cash + short-term investments totalled ~$2.29 B. Shareholders’ equity improved to $631.7 M. Current liabilities grew to $897.2 M after the 0% convertible notes ($630.1 M) moved current; total liabilities stand at $2.35 B.
Strategic updates: 1) Ono deal brings up to $940 M future milestones; 2) AstraZeneca advanced opemalirsen into Phase 2b; 3) first independent commercial launch with FDA-approved TRYNGOLZA for FCS. Company maintains single-segment reporting and full valuation allowance on deferred tax assets.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
